How the town hall presidential debate works

How the town hall presidential debate works

Presidential debates are unpredictable enough with just two candidates and a moderator. And this Sunday's will add questions from a live audience of undecided voters on top of that. The upcoming presidential debate between Hillary Clinton and Donald Trump will be a town-hall format, which means half the questions will come from uncommitted voters in → Read More

Here's Why Geron Corporation Tumbled 16% in September

Here's Why Geron Corporation Tumbled 16% in September

What happened Shares of Geron Corporation (NASDAQ:GERN), a small-cap clinical-stage biotech company with a focus on developing therapies to treat cancer, fell 16% during September, according to data from S&P Global Market Intelligence. The majority of the decline can be traced to Geron's Sept. 12 update for its two ongoing studies involving lead drug imetelstat. → Read More

Bernie Sanders, Elizabeth Warren scold Wells Fargo over military treatment

Bernie Sanders, Elizabeth Warren scold Wells Fargo over military treatment

Elizabeth Warren: Wells Fargo CEO should resign Wells Fargo is catching serious heat from Senators Bernie Sanders and Elizabeth Warren over its treatment of the military after the bank got caught illegally repossessing service members' cars. Warren fired off another letter to Wells Fargo CEO John Stumpf this week rattling off a series of pointed → Read More

Is Kroger going to buy Whole Foods?

Is Kroger going to buy Whole Foods?

5 stunning stats about Whole Foods Will $6 bottles of asparagus water soon be coming to a Kroger, Ralphs or Harris Teeter near you? Whole Foods stock shot up 5% Thursday and briefly rose again Friday on chatter that supermarket king Kroger may want to buy the troubled organic grocer. But is Whole Foods (WFM) → Read More

This Game Changer Fueled Apache Corporation's 28.3% Surge in September

This Game Changer Fueled Apache Corporation's 28.3% Surge in September

What happened Shares of Apache (NYSE:APA) skyrocketed nearly 30% last month after the company announced the massive Alpine High oil discovery in Texas while analysts and OPEC added more fuel to the fire. So what In early September, Apache announced the discovery of a significant new oil discovery in the Permian Basin. The 3 billion → Read More

Mexico's former president: Global infrastructure needs an upgrade

Mexico's former president: Global infrastructure needs an upgrade

One of the few things that both Hillary Clinton and Donald Trump agree on is that the United States needs to spend more on infrastructure. That's because America's roads, rails, and pipes are in dire need of an upgrade. The American Society of Civil Engineers estimates that $3.6 trillion of investment is necessary by 2020. → Read More

Mexico's former president: Global infrastructure needs an upgrade

Mexico's former president: Global infrastructure needs an upgrade

One of the few things that both Hillary Clinton and Donald Trump agree on is that the United States needs to spend more on infrastructure. That's because America's roads, rails, and pipes are in dire need of an upgrade. The American Society of Civil Engineers estimates that $3.6 trillion of investment is necessary by 2020. → Read More

Did Bass Pro Shops Just Waste $5.5 Billion on Cabela's?

Did Bass Pro Shops Just Waste $5.5 Billion on Cabela's?

After months of anticipation Bass Pro Shops finally made its play for rival outdoor equipment company Cabela's (NYSE:CAB) and hooked the retailer with an offer of $65.50 per share, or about $5.5 billion, including debt. Although the deal will create a behemoth with almost 200 stores that stretch across the country, 40,000 employees, and a → Read More

What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?

What's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?

Another once-promising drug has failed. Alnylam Pharmaceuticals (NASDAQ:ALNY) announced on Oct. 5 that it was discontinuing development of revusiran in treating hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). The drug had been in a late-stage study and mid-stage study. The company said that its independent committee monitoring the late-stage study recommended that the benefits of the → Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.